VedaBio has entered into agreement with Mammoth Biosciences to enhance its CRISPR-based molecular detection platform for ...

It has long been understood that orchard automation is the key for industry’s profitability and sustainability. As part of ...

VedaBio announces non-exclusive license agreement with Mammoth Biosciences for use of select CRISPR-based technologies in diagnostic applications ...

CRISPR technology could one day create “designer babies, ” raising major ethical and social inequality concerns.

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. CRISPR Therapeutics AG ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced ...

A study, published in the journal Frontiers in Genome Editing, outlines a method for editing single plant cells from sterile ...

The nonexclusive license potentially broadens VedaBio's platform while making it simpler and more cost-effective.

Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a rare condition associated with stroke, aortic dissection ...

Researchers have unveiled a new type of nanostructure that dramatically improves CRISPR delivery. Called lipid nanoparticle ...

Researchers engineered a bespoke CRISPR-Cas9 gene-editing enzyme to develop a potential therapy for MSMDS, which ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 4:30 PM EDT ...